polytaxel

Polytaxel is an investigational chemotherapy drug developed by Hyundai Bioscience, designed to deliver docetaxel—the active pharmaceutical ingredient—in a novel formulation. Unlike standard docetaxel regimens, Polytaxel aims to complete chemotherapy with as few as two doses over eight days, potentially allowing for pain-free cancer treatment with reduced toxicity and minimal side effects. The unique dosing method is intended to eliminate the need for recovery breaks between cycles, enabling patients to maintain a relatively normal lifestyle during therapy. Preclinical studies have shown high tumor remission rates (67%–83%) with minimal toxicity. Polytaxel is currently in phase 1 clinical trials for pancreatic cancer in Australia[2][8].

Brand names

POLYTAXEL

Other names

POLYTAXEL